TY - JOUR
T1 - Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Control
T2 - A MASK-air Real-World Study
AU - Sousa-Pinto, Bernardo
AU - Louis, Gilles
AU - Rodrigues, Jorge
AU - Giuliano, Antonio Francesco Maria
AU - Baiardini, Ilaria
AU - Braido, Fulvio
AU - Czarlewski, Wienczyslawa
AU - Bedbrook, Anna
AU - Haahtela, Tari
AU - Valiulis, Arunas
AU - Brussino, Luisa
AU - Cecchi, Lorenzo
AU - Cruz, Alvaro A.
AU - Gemicioglu, Bilun
AU - Fokkens, Wytske J.
AU - Ivancevich, Juan Carlos
AU - Klimek, Ludger
AU - Kraxner, Helga
AU - Kuna, Piotr
AU - Kupczyk, Maciej
AU - Kvedariene, Violeta
AU - Larenas-Linnemann, Désirée
AU - Louis, Renaud
AU - Nadif, Rachel
AU - Niedoszytko, Marek
AU - Okamoto, Yoshitaka
AU - Ollert, Markus
AU - Papadopoulos, Nikolaos G.
AU - Patella, Vincenzo
AU - Pawankar, Ruby
AU - Pham-Thi, Nhân
AU - Pfaar, Oliver
AU - Regateiro, Frederico S.
AU - Roche, Nicolas
AU - Rouadi, Philip W.
AU - Samolinski, Boleslaw
AU - Sastre, Joaquin
AU - Savouré, Marine
AU - Scichilone, Nicola
AU - Sheikh, Aziz
AU - Taborda-Barata, Luís
AU - Toppila-Salmi, Sanna
AU - Yorgancioglu, Arzu
AU - Zidarn, Mihaela
AU - Anto, Josep M.
AU - Zuberbier, Torsten
AU - Canonica, G. Walter
AU - Ventura, Maria Teresa
AU - Fonseca, João A.
AU - Pétré, Benoit
AU - Bousquet, Jean
N1 - Funding Information:
This study was partly funded by a grant from the University of Liège , Belgium. MASK-air has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Région Languedoc Roussillon and PACA; Twinning, EIP on AHA, DG Santé, and DG Connect; H2020 and Horizon Europe) and educational grants from Mylan-Viatris , ALK, GSK, Novartis, and Uriach.
Publisher Copyright:
© 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023/12
Y1 - 2023/12
N2 - Background: EQ-5D-5L (EuroQOL, 5 Domains, 5 Levels) is a widely used health-related quality-of-life instrument, comprising 5 domains. However, it is not known how each domain is impacted by rhinitis or asthma control. Objective: To assess the association between rhinitis or asthma control and the different EQ-5D-5L domains using data from the MASK-air mHealth app. Methods: In this cross-sectional study, we assessed data from all MASK-air users (2015-2021; 24 countries). For the levels of each EQ-5D-5L domain, we assessed rhinitis and asthma visual analog scales (VASs) and the combined symptom-medication score (CSMS). We built ordinal multivariable models assessing the adjusted association between VAS/CSMS values and the levels of each EQ-5D-5L domain. Finally, we compared EQ-5D-5L data from users with rhinitis and self-reported asthma with data from users with rhinitis alone. Results: We assessed 5354 days from 3092 users. We observed an association between worse control of rhinitis or asthma (higher VASs and CSMS) and worse EQ-5D-5L levels. In multivariable models, all VASs and the CSMS were associated with higher levels of pain/discomfort and daily activities. For anxiety/depression, the association was mostly observed for rhinitis-related tools (VAS nose, VAS global, and CSMS), although the presence of self-reported asthma was also associated with worse anxiety/depression. Worse mobility (“walking around”) was particularly associated with VAS asthma and with the presence of asthma. Conclusions: A worse rhinitis control and a worse asthma control are associated with higher EQ-5D-5L levels, particularly regarding pain/discomfort and activity impairment. Worse rhinitis control is associated with worse anxiety/depression, and poor asthma control with worse mobility.
AB - Background: EQ-5D-5L (EuroQOL, 5 Domains, 5 Levels) is a widely used health-related quality-of-life instrument, comprising 5 domains. However, it is not known how each domain is impacted by rhinitis or asthma control. Objective: To assess the association between rhinitis or asthma control and the different EQ-5D-5L domains using data from the MASK-air mHealth app. Methods: In this cross-sectional study, we assessed data from all MASK-air users (2015-2021; 24 countries). For the levels of each EQ-5D-5L domain, we assessed rhinitis and asthma visual analog scales (VASs) and the combined symptom-medication score (CSMS). We built ordinal multivariable models assessing the adjusted association between VAS/CSMS values and the levels of each EQ-5D-5L domain. Finally, we compared EQ-5D-5L data from users with rhinitis and self-reported asthma with data from users with rhinitis alone. Results: We assessed 5354 days from 3092 users. We observed an association between worse control of rhinitis or asthma (higher VASs and CSMS) and worse EQ-5D-5L levels. In multivariable models, all VASs and the CSMS were associated with higher levels of pain/discomfort and daily activities. For anxiety/depression, the association was mostly observed for rhinitis-related tools (VAS nose, VAS global, and CSMS), although the presence of self-reported asthma was also associated with worse anxiety/depression. Worse mobility (“walking around”) was particularly associated with VAS asthma and with the presence of asthma. Conclusions: A worse rhinitis control and a worse asthma control are associated with higher EQ-5D-5L levels, particularly regarding pain/discomfort and activity impairment. Worse rhinitis control is associated with worse anxiety/depression, and poor asthma control with worse mobility.
KW - Allergic rhinitis
KW - Asthma
KW - Mobile health
KW - Quality of life
UR - https://www.scopus.com/pages/publications/85169827453
UR - https://pubmed.ncbi.nlm.nih.gov/37572753
U2 - 10.1016/j.jaip.2023.08.006
DO - 10.1016/j.jaip.2023.08.006
M3 - Article
C2 - 37572753
SN - 2213-2198
VL - 11
SP - 3742-3751.e9
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 12
ER -